Pharmacovigilance Workshop

50 %
50 %
Information about Pharmacovigilance Workshop

Published on May 30, 2007

Author: inemet

Source: slideshare.net

Description

PharmaCon2007 Conference Dubrovnik Croatia

Pharmacovigilance Workshop

Outline What is Pharmacovigilance? Need for Pharmacovigilance? The concept of Pharmacovigilance system Pharmacovigilance in Croatia Introduction to Workshop Workshop

What is Pharmacovigilance?

Need for Pharmacovigilance?

The concept of Pharmacovigilance system

Pharmacovigilance in Croatia

Introduction to Workshop

Workshop

What is Pharmacovigilance? pharmakon (Greek) = medicinal substance vigilia (Latin) = to keep watch Science and activities relating to the detection, assessment, understanding and prevention of adverse effects and any other medicine-related problem (WHO) Includes clinical development and postmarketing surveillance OBJECTIVES

pharmakon (Greek) = medicinal substance

vigilia (Latin) = to keep watch

Science and activities relating to the detection, assessment, understanding and prevention of adverse effects and any other medicine-related problem (WHO)

Includes clinical development and postmarketing surveillance

OBJECTIVES

Objectives of Pharmacovigilance Long term monitoring of drug-safety in order to: Identify previously unknown hazards Evaluate changes in benefits and risks Provide optimal information to users Take action to promote safer use Monitor impact of action taken

Long term monitoring of drug-safety in order to:

Identify previously unknown hazards

Evaluate changes in benefits and risks

Provide optimal information to users

Take action to promote safer use

Monitor impact of action taken

Need for Pharmacovigilance ? ? ? ? ? ?

Need for Pharmacovigilance

From test tube to the market – PRECLINICAL RESEARCH SYNTHESIS CANDIDATES SAFETY, TOLERABILITY & PHARMACOKINETICS Toxicity testing , reproductive toxicology, carcinogenicity, genotoxicity, toxicokinetics DRUG SCREENING activity & selectivity = Pharmacological profile

From test tube to the market – CLINICAL RESEARCH PHASE I PHASE III PHASE II “ First-in-Man Trial” Pharmacokinetics Metabolism Pharmacology Safety (early effectiveness) 20-80 HEALTHY VOLUNTEERS Preliminary data on efficacy for a particular indication(s) Short-term Adverse Drug Reactions Dose range SEVERAL HUNDRED PATIENTS WITH DISEASES OR CONDITION SEVERAL HUNDRED TO THOUSAND PATIENTS Efficacy and safety for overall benefit-risk assessment Product information APPROVAL

? Limitations of Clinical Study Data ? Variable (compliance?) Fixed Dose Flexible; less information Rigorous; more information Conditions Usually present Avoided Concomitant medication and illness All Pregnant, children, elderly excluded Population Years Weeks Duration Thousands to millions Hundreds (rarely thousands) Number of patients Clinical Practice Clinical trials

Drug Safety Information Formulation (STRUCTURE ACTIVITY RELATIONSHIP) Preclinical studies (TOXICOLOGY, PHARMACOLOGY, PHARMACOKINETICS) Clinical studies (IDENTIFICATION OF ADRs, CHARACTERISATION, CAUSALITY, FREQUENCY, MANAGING) Pre marketing RARE ADRs? CHRONIC USE? DELAYED ADRs? INTERACTIONS? CHILDREN/ELDERLY?

From test tube to the market – CLINICAL RESEARCH PHASE I PHASE III PHASE II “ First-in-Man Trial” Pharmacokinetics Metabolism Pharmacology Safety (early effectiveness) 20-80 HEALTHY VOLUNTEERS Preliminary data on efficacy for a particular indication(s) Short-term Adverse Drug Reactions Dose range SEVERAL HUNDRED PATIENTS WITH DISEASES OR CONDITION SEVERAL HUNDRED TO THOUSAND PATIENTS Efficacy and safety for overall benefit-risk assessment Product information APPROVAL POSTMARKETING SURVEILLANCE

Postmarketing surveillance Additional data on safety and efficacy that could not be collected through Phase I-III

Additional data on safety and efficacy that

could not be collected through Phase I-III

Postmarketing surveillance TOOLS FOR COLLECTION Spontaneous reporting unsolicited communication by Healthcare professional or Consumer to a company, regulatory authority or other organisation Post-Authorisation Safety Studies (Phase IV): Interventional (Clinical Trial) Non-interventional (observational) Medicinal product is prescribed in the usual manner in accordance with the terms of the Marketing Authorisation Registries, Named-patient use programmes, Surveys of patients and Healthcare Providers…

Spontaneous reporting

unsolicited communication by Healthcare professional or Consumer to a company, regulatory authority or other organisation

Post-Authorisation Safety Studies (Phase IV):

Interventional (Clinical Trial)

Non-interventional (observational)

Medicinal product is prescribed in the usual manner in accordance with the terms of the Marketing Authorisation

Registries, Named-patient use programmes, Surveys of patients and Healthcare Providers…

Withdrawals from the market as a result of spontaneous reporting 1998 1997 Serious hepatotoxic effect bromfenac 1998 1985 Fatal cardiac arrythmias terfenadine 1992 1992 Haemolytic anemia temafloxacin 1991 1987 Excessive mortality encainide 1982 1982 Onycholysis, renal, liver, bone marrow toxicity benoxaprofen 1975 1970 Blindness practolol Year of withdrawal Year of approval Reason for withdrawal INN

Need for Pharmacovigilance ! ! ! ! ! !

Need for Pharmacovigilance

Histor ical Background Thalidomide 1960 marketed in 46 countries (hypnotic, prevention of nausea in pregnancy) Heavily promoted 1960 first reports of deformed infants (phoecomelia) tot. more than 20 000 cases

Thalidomide

1960 marketed in 46 countries (hypnotic, prevention of nausea in pregnancy)

Heavily promoted

1960 first reports of deformed infants (phoecomelia) tot. more than 20 000 cases

Histor ical Background Direct result of thalidomide: USA : 1962 amendment to Federal Food, drug & Cosmetic Act-required both safety & efficacy da t a EU : EC Directive 65/65 UK: 1964 Yellow card scheme WHO : 1968 Programme for International Drug Monitoring

Direct result of thalidomide:

USA : 1962 amendment to Federal Food, drug & Cosmetic Act-required both safety & efficacy da t a

EU : EC Directive 65/65

UK: 1964 Yellow card scheme

WHO : 1968 Programme for International Drug Monitoring

The WHO set up its International Drug Monitoring Programme after the thalidomide disaster Since 1978 the Programme has been carried out by the Uppsala Monitoring Centre (UMC) in Sweden responsible for the collection of data about adverse drug reactions from around the world, especially from countries that are members of the WHO, and the generation of signals of drugs which might possibly have problematic side-effects

The WHO set up its International Drug Monitoring Programme after the thalidomide disaster

Since 1978 the Programme has been carried out by the Uppsala Monitoring Centre (UMC) in Sweden

responsible for the collection of data about adverse drug reactions from around the world, especially from countries that are members of the WHO, and the generation of signals of drugs which might possibly have problematic side-effects

82 Official Member Countries 17 Associate Member Countries WHO Database  3.7 million reports (2006)

82 Official Member Countries

17 Associate Member Countries

WHO Database  3.7 million reports (2006)

The Concept of Pharmacovigilance System

Pharmacovigilance – concerned parties Competent Authorities (National Agencies, European Medicines Agency) Healthcare Professionals: Voluntary reporting or Mandatory reporting WHO Pharmaceutical Industry (Marketing Authorisation Holder & Sponsor of Clinical Trials) Patients: Complain or Complain & Report

Collect Identify Evaluate Take action INDIVIDUAL REPORTS

Reporting forms CIOMS I form Developed by CIOMS working group in 1990 (Council for International Organizations for Medical Sciences =industry+regulators) Standard form for reporting ADRs by the pharmaceutical industry

Developed by CIOMS working group in 1990 (Council for International Organizations for Medical Sciences =industry+regulators)

Standard form for reporting ADRs by the pharmaceutical industry

Reporting forms National reporting forms Every country with a developed Pharmacovigilance system has its own form Based on the CIOMS I reporting form Adjusted to the national legal requirements & praxis

Every country with a developed Pharmacovigilance system has its own form

Based on the CIOMS I reporting form

Adjusted to the national legal requirements & praxis

Minimum information for a valid report Identifiable source (Healthcare professional) Identifiable patient Suspected product Suspected reaction

Identifiable source (Healthcare professional)

Identifiable patient

Suspected product

Suspected reaction

What needs to be collected? Adverse Drug Reactions Outcome of a use of a medicinal product during pregnancy Adverse reactions during breastfeeding Paediatric data Data from compassionate/named-patient use Lack of efficacy Suspected transmission of infectious agents Overdose, abuse and misuse Medication errors

Adverse Drug Reactions

Outcome of a use of a medicinal product during pregnancy

Adverse reactions during breastfeeding

Paediatric data

Data from compassionate/named-patient use

Lack of efficacy

Suspected transmission of infectious agents

Overdose, abuse and misuse

Medication errors

Healthcare Professionals AGENCY National ADR Database MAH - PhV Qualified Person Individual answer to the reporter (Croatia, New Zealand…) WHO-UMC Database EudraVigilance - Database Marketing Authorisation Holder (through sales representatives) MAH -Central Office Information about the ADRs and other important information about the safety profile of the drug The Agency sends new Report forms Prepaid envelope for ADRs reporting Part of continuos medical education European Medicines Agency How is it collected?

Information about the ADRs and other important information about the safety profile of the drug

The Agency sends new Report forms

Prepaid envelope for ADRs reporting

Part of continuos medical education

Collect PSUR Identify Evaluate Take action INDIVIDUAL REPORTS

A regulatory document prepared by the Marketing Authorisation Holder & submitted to the Agency Worldwide post-authorisation safety experience includes information on ALL ADRs collected irrespective of the reporting country Includes scientific evaluation of the risk-benefit balance EU requirements: first 2 years after authorisation  every 6 months next 2 years  once a year after that  every 3 years PSUR PERIODIC SAFETY UPDATE REPORT

A regulatory document prepared by the Marketing Authorisation Holder & submitted to the Agency

Worldwide post-authorisation safety experience

includes information on ALL ADRs collected irrespective of the reporting country

Includes scientific evaluation of the risk-benefit balance

EU requirements:

first 2 years after authorisation  every 6 months

next 2 years  once a year

after that  every 3 years

Collect SIGNAL DETECTION PSURs Identify Evaluate Take action INDIVIDUAL REPORTS

Signal Detection Today: Large & Complex computerised systems Signal: new, previously unknown safety information

Collect SIGNAL DETECTION PSURs Identify Evaluate Take action INDIVIDUAL REPORTS CLINICAL EVALUATION REGULATORY ACTION INFORMATION TO HEALTHCARE PROFESSIONALS AND THE PUBLIC

Regulatory actions on the basis of ADR reports Changes in the Summary of Product Characteristics (SPC) and Patient Information Leaflets (PIL) in the part which is dealing with the product safety

Changes in the Summary of Product Characteristics (SPC) and Patient Information Leaflets (PIL) in the part which is dealing with the product safety

Product Information Summary of the Product Characteristics (SPC) basis of information for Healthcare Professionals on how to use the medicinal product safely and effectively Patient Information Leaflet (PIL) drawn up in accordance with the SPC

Summary of the Product Characteristics (SPC)

basis of information for Healthcare Professionals on how to use the medicinal product safely and effectively

Patient Information Leaflet (PIL)

drawn up in accordance with the SPC

Summary of the Product Characteristics (SPC) 1. NAME OF THE MEDICINAL PRODUCT 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 3. PHARMACEUTICAL FORM 4. CLINICAL PARTICULARS 4.1 Therapeutic indications 4.2 Posology and method of administration 4.3 Contraindications 4.4 Special warnings and precautions for use 4.5 Interaction with other medicinal products and other forms of interaction 4.6 Pregnancy and lactation 4.7 Effects on ability to drive and use machines 4.8 Undesirable effects 4.9 Overdose 5. PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties 5.2 Pharmacokinetic properties 5.3 Preclinical safety data 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients 6.2 Incompatibilities 6.3 Shelf life 6.4 Special precautions for storage 6.5 Nature and contents of container 6.6 Special precautions for disposal and other handling 7. MARKETING AUTHORISATION HOLDER 8. MARKETING AUTHORISATION NUMBER(S) 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 10. DATE OF REVISION OF THE TEXT LEGAL CATEGORY

Summary of the Product Characteristics (SPC)

1. NAME OF THE MEDICINAL PRODUCT

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

3. PHARMACEUTICAL FORM

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

4.2 Posology and method of administration

4.3 Contraindications

4.4 Special warnings and precautions for use

4.5 Interaction with other medicinal products and other forms of interaction

4.6 Pregnancy and lactation

4.7 Effects on ability to drive and use machines

4.8 Undesirable effects

4.9 Overdose

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

5.2 Pharmacokinetic properties

5.3 Preclinical safety data

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

6.2 Incompatibilities

6.3 Shelf life

6.4 Special precautions for storage

6.5 Nature and contents of container

6.6 Special precautions for disposal and other handling

7. MARKETING AUTHORISATION HOLDER

8. MARKETING AUTHORISATION NUMBER(S)

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

10. DATE OF REVISION OF THE TEXT

LEGAL CATEGORY

Regulatory actions on the basis of ADR reports Changes in the Summary of Product Characteristics (SPC) and Patient Information Leaflets (PIL) in the part which is dealing with the product safety Changes in classification: From Over the counter to Prescription only Medicine From renewable prescription to non-renewable Special medical prescription Restricted prescription Marketing Authorisation withdrawal Batch recall based on clustering of ADRs

Changes in the Summary of Product Characteristics (SPC) and Patient Information Leaflets (PIL) in the part which is dealing with the product safety

Changes in classification:

From Over the counter to Prescription only Medicine

From renewable prescription to non-renewable

Special medical prescription

Restricted prescription

Marketing Authorisation withdrawal

Batch recall based on clustering of ADRs

Information to Healthcare Professionals and the Public In addition to the information provided in Product Information when there are new important safety findings, withdrawals, suspensions, revocations… Tools: Direct Healthcare Professional Communication  “Dear Doctor Letters” Web Newsletters Publications

In addition to the information provided in Product Information

when there are new important safety findings, withdrawals, suspensions, revocations…

Tools:

Direct Healthcare Professional Communication  “Dear Doctor Letters”

Web

Newsletters

Publications

Pharmacovigilance in Croatia

Pharmacovigilance in Croatia

 

Agency for Medicinal Products and Medical Devices, Ksaverska cesta 4, Zagreb tel. 01/ 46 93 830; fax. 01/ 46 73 275

Pharmacovigilance Unit ADR report assessment (expectedness, seriousness and causality assessment) Individual answer to the reporters Entering ADR reports into the Agency’s Database PSUR assessment Safety news monitoring Web-site regularly updated with Pharmacovigilance news C ollaboration with Public Relations Office (newspapers, radio, TV) Education of Healthcare Professionals & Industry

ADR report assessment (expectedness, seriousness and causality assessment)

Individual answer to the reporters

Entering ADR reports into the Agency’s Database

PSUR assessment

Safety news monitoring

Web-site regularly updated with Pharmacovigilance news

C ollaboration with Public Relations Office (newspapers, radio, TV)

Education of Healthcare Professionals & Industry

Educational activities Workshop about the role of physicians and pharmacists in adverse reaction reporting and pharmacovigilance system in Croatia: Over 1200 participants in 10 different cities free of charge recognised as a part of continuing education by the Croatian health - care professionals chambers

Workshop about the role of physicians and pharmacists in adverse reaction reporting and pharmacovigilance system in Croatia:

Over 1200 participants

in 10 different cities

free of charge

recognised as a part of continuing education by the Croatian health - care professionals chambers

Educational activities

Educational activities - results Number of reports increased N ew reporters Better quality of reports Healthcare professionals recognise the Agency as a reliable source of information

Number of reports increased

N ew reporters

Better quality of reports

Healthcare professionals recognise the Agency as a reliable source of information

Educational activities - results Percentage of reports received from pharmacists increased

Percentage of reports received from pharmacists increased

 

Introduction to the Workshop

What is an Adverse Reaction? A reaction to a drug which is harmful and unintended and which occurs at doses normally used in man for the prophylaxis, diagnosis or treatment of disease or the modification of physiological function Adverse reaction vs Adverse event Adverse event: time relationship with drug + causal relationship with drug -

A reaction to a drug which is harmful and unintended and which occurs at doses normally used in man for the prophylaxis, diagnosis or treatment of disease or the modification of physiological function

Adverse reaction vs Adverse event

Adverse event: time relationship with drug +

causal relationship with drug -

Types of Adverse Reactions Type A (augmented) P harmacological mechanism Excess of desired pharmacology ( β -blockers, antidiabetics, diuretics…) Unwanted but documented pharmacology ( antihistaminics, Ca-chanel blockers, NSAID s ) Type B (bizarre) Specific, characteristic reactions S usceptible individuals only Anaphylaxis/anaphylactoid, cytotoxic, immune complex, cell mediated, unknown

Type A (augmented)

P harmacological mechanism

Excess of desired pharmacology ( β -blockers, antidiabetics, diuretics…)

Unwanted but documented pharmacology ( antihistaminics, Ca-chanel blockers, NSAID s )

Type B (bizarre)

Specific, characteristic reactions

S usceptible individuals only

Anaphylaxis/anaphylactoid, cytotoxic, immune complex, cell mediated, unknown

Types of Adverse Reactions Type C (chronic) Due to repeated insult by the drug T i me relationship variable Mechanism uncertain Type D (delayed) Take time to develop Carcinogenesis, teratogenesis

Type C (chronic)

Due to repeated insult by the drug

T i me relationship variable

Mechanism uncertain

Type D (delayed)

Take time to develop

Carcinogenesis, teratogenesis

Types of Adverse Reactions Type E after termination of therapy symptoms of abstinence rebound phenomena Type F ( failure ) therapeutic failure inefficacy (vaccines, contraceptives)

Type E

after termination of therapy

symptoms of abstinence

rebound phenomena

Type F ( failure )

therapeutic failure

inefficacy (vaccines, contraceptives)

Serious adverse reaction Fatal Life threatening Disabling or incapacitating Results in, or prolongs hospitalisation Is a co n genital anomaly/birth defect In medical judgement may jeopardise the patient

Fatal

Life threatening

Disabling or incapacitating

Results in, or prolongs hospitalisation

Is a co n genital anomaly/birth defect

In medical judgement may jeopardise the patient

Unexpected Adverse Reaction Not mentioned in the S ummary of P roduct C haracteristics (SPC) – any adverse drug reaction whose nature, severity or outcome is inconsistent with information in the SPC

Not mentioned in the S ummary of P roduct C haracteristics (SPC) – any adverse drug reaction whose nature, severity or outcome is inconsistent with information in the SPC

Causality Assessment Definite/certain Probable Possible Causality unclear (unlikely) None  Adverse Drug Event! Uncertain/unknown Un-assessable Adverse Drug Reaction!

Definite/certain

Probable

Possible

Causality unclear (unlikely)

None  Adverse Drug Event!

Uncertain/unknown

Un-assessable

Definite/certain Very close time relationship Single suspected drug Positive de-challenge and re-challenge No other likely cause + DE-CHALLENGE=when the drug is stopped the reaction resolves + RE-CHALLENGE=the reaction reappears when the drug is restarted

Very close time relationship

Single suspected drug

Positive de-challenge and re-challenge

No other likely cause

+ DE-CHALLENGE=when the drug is stopped the reaction resolves

+ RE-CHALLENGE=the reaction reappears when the drug is restarted

Probable Close time relationship Single suspected drug Positive de-challenge N o other likely cause

Close time relationship

Single suspected drug

Positive de-challenge

N o other likely cause

Possible Plausible time relationship Single or multiple suspected drugs Not recovered, or needed therapy Other possible medical explanation, but not likely

Plausible time relationship

Single or multiple suspected drugs

Not recovered, or needed therapy

Other possible medical explanation, but not likely

Causality unclear (unlikely) Implausible time relationship Implausible biological association Single or multiple suspected drugs Not recover ed , or needed therapy Other likely cause(s)

Implausible time relationship

Implausible biological association

Single or multiple suspected drugs

Not recover ed , or needed therapy

Other likely cause(s)

WHO causality classification Probable Unlikely Unlikely Possible No data on dechallenge Possible Possible Dechallenge Probable No Dechallenge i rechallenge Certain Other factors Time relationship

Time for exercise!

Case 1 43 year–old man had been taking Painomore tablets 200 mg (ibuprofen) occasionally for headache for the past 5 years. On 15.10.2005. he is coming to your pharmacy and asking for another analgetic because he was hospitalised a week ago after developing difficulty with breathing and severe pruritus and rash on his hands, back and abdomen after taking Painomore . Previously, on one occasion, he also developed a rash after taking Painomore but the symptom lasted for 6 hours and resolved spontaneously, so he didn’t visit his doctor. The second time he had terrible headache and he didn't have anything else at home. He is not taking any other medicine.

43 year–old man had been taking Painomore tablets 200 mg (ibuprofen) occasionally for headache for the past 5 years. On 15.10.2005. he is coming to your pharmacy and asking for another analgetic because he was hospitalised a week ago after developing difficulty with breathing and severe pruritus and rash on his hands, back and abdomen after taking Painomore . Previously, on one occasion, he also developed a rash after taking Painomore but the symptom lasted for 6 hours and resolved spontaneously, so he didn’t visit his doctor. The second time he had terrible headache and he didn't have anything else at home. He is not taking any other medicine.

Painomore tablets 200 mg Summary of the product characteristics: 4.8 Adverse drug reactions: Hypersensitivity: Hypersensitivity reactions have been reported following treatment with ibuprofen. These may consist of (a) non-specific allergic reaction and anaphylaxis, (b) respiratory tract reactivity comprising asthma, aggravated asthma, bronchospasm or dyspnoea, or (c) assorted skin disorders, including rashes of various types, pruritus, urticaria, purpura, angioedema and, less commonly, bullous dermatoses (including epidermal necrolysis and erythema multiforme).

Painomore tablets 200 mg Summary of the product characteristics:

4.8 Adverse drug reactions:

Hypersensitivity: Hypersensitivity reactions have been reported following treatment with ibuprofen. These may consist of (a) non-specific allergic reaction and anaphylaxis, (b) respiratory tract reactivity comprising asthma, aggravated asthma, bronchospasm or dyspnoea, or (c) assorted skin disorders, including rashes of various types, pruritus, urticaria, purpura, angioedema and, less commonly, bullous dermatoses (including epidermal necrolysis and erythema multiforme).

1. Suspected drug is: 2. What are the symptoms of adverse drug reaction? 3. Is this ADR serious? 4. If yes, why? 5. Is this reaction expected? 6. Drug-reaction causality assessment: certain probable possible unlikely not related 7. What advice you would give to the patient?

1. Suspected drug is:

2. What are the symptoms of adverse drug reaction?

3. Is this ADR serious?

4. If yes, why?

5. Is this reaction expected?

6. Drug-reaction causality assessment:

certain

probable

possible

unlikely

not related

7. What advice you would give to the patient?

Case 2 74 year–old woman, asks you for advice because she is feeling sad and depressed since her husband died 6 months ago. You recommend her to take an OTC herbal antidepressant Proactive tablets (St. John's Worth) two times a day. Two months after she comes to your pharmacy to buy a 3rd box of Proactive . In a short conversation you find out that she is feeling better, but that three weeks ago a mild dizziness appeared. Patient is not especially worried about this symptom because she attributes it to her age. She didn’t contact her doctor yet. She is also taking acetylsalicylic acid tablets 100 mg.

74 year–old woman, asks you for advice because she is feeling sad and depressed since her husband died 6 months ago. You recommend her to take an OTC herbal antidepressant Proactive tablets (St. John's Worth) two times a day. Two months after she comes to your pharmacy to buy a 3rd box of Proactive . In a short conversation you find out that she is feeling better, but that three weeks ago a mild dizziness appeared. Patient is not especially worried about this symptom because she attributes it to her age. She didn’t contact her doctor yet. She is also taking acetylsalicylic acid tablets 100 mg.

Proactive Summary of the product characteristics : 4.8. Adverse drug reactions: very rare: nausea, rash, weakness or agitation

Proactive Summary of the product characteristics :

4.8. Adverse drug reactions:

very rare: nausea, rash, weakness or agitation

1. Suspected drug is: 2. What are the symptoms of adverse drug reaction? 3. Is this ADR serious? 4. If yes, why? 5. Is this reaction expected? 6. Drug-reaction causality assessment: certain probable possible unlikely not related 7. What advice you would give to the patient?

1. Suspected drug is:

2. What are the symptoms of adverse drug reaction?

3. Is this ADR serious?

4. If yes, why?

5. Is this reaction expected?

6. Drug-reaction causality assessment:

certain

probable

possible

unlikely

not related

7. What advice you would give to the patient?

Add a comment

Related presentations

Related pages

Pharmacovigilance I - Dr. Notghi Academy

Target audience. This workshop teaches the fundamentals of pharmacovigilance in theory and practice and is ideally suited for both those new to ...
Read more

Workshop: measuring the impact of pharmacovigilance activities

Workshop: measuring the impact of pharmacovigilance activities EMA/95397/2016 Page 7/9 Xavier Kurz . European Medicines Agency . 14.00 Panel discussion
Read more

WHO | WHO Training Workshop on Pharmacovigilance

WHO Training Workshop on Pharmacovigilance Basic introduction and specifics for malaria programme 24 March - 2 April 2003, Lusaka, Zambia
Read more

7th Annual Pharmacovigilance Asia Summit

Pre-Conference Workshop - Monday ... The 7th Annual Pharmacovigilance Asia Summit once again gathers global and ... "The IQPC Pharmacovigilance ...
Read more

Pharmacovigilance I WORKSHOP - dr-notghi-cro.de

Target audience. This workshop teaches the fundamentals of pharmacovigilance in theory and practice and is ideally suited for both those new to ...
Read more

European Medicines Agency - Pharmacovigilance - Good ...

Good pharmacovigilance practices (GVP) are a set of measures drawn up to facilitate the performance of pharmacovigilance in the European Union (EU).
Read more

Pharmacovigilance

Pharmacovigilance since beginning has been a compliance driven activity, wherein your regulatory compliance determines company’s risk assessment scores ...
Read more